07.01.2017
Fresenius Medical Care AG & Co. KGaA DE0005785802
DGAP-Adhoc: Fresenius Medical Care AG & Co. KGaA: Impact of potential regulation change
DGAP-Ad-hoc: Fresenius Medical Care AG & Co. KGaA / Key word(s): Statement
Fresenius Medical Care AG & Co. KGaA: Impact of potential regulation change
07-Jan-2017 / 02:31 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by
DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Fresenius Medical Care: Impact of potential regulation change
Centers for Medicare and Medicaid Services (CMS) promulgated a new
regulation regarding premium assistance programs that help to fund health
insurance premiums for patients with end stage renal disease (ESRD). Many
financially needy Americans receive grants from nonprofit charities to help
them obtain health insurance. For decades, the American Kidney Fund (AKF)
has provided such premium assistance to ESRD patients.
The new regulation, which is scheduled to become effective on January 13,
2017, threatens to put an end to premium assistance for certain ESRD
patients. The regulation, should it become effective, and the continuing
efforts by insurers - through their discussions with CMS and otherwise - to
reject premium assistance for ESRD patients, may result in a material
adverse effect on our business. Between 700 and 2,000 FMCNA ESRD patients
who currently use premium assistance in connection with individual market
plans on and off the exchanges may be impacted by the regulation and/or
continuing insurer efforts to reject premium assistance.
Fresenius Medical Care Holdings, Inc. (FMCNA) has joined other providers
and patient advocates in filing a lawsuit challenging the rulemaking
process and stop the regulation to become effective.
On January 3, 2017, FMCNA accepted service of a subpoena from the United
States Attorney for the District of Massachusetts calling for the
production of information related to the premium assistance program
operated by the AKF. FMCNA is cooperating with this investigation.
---------------------------------------------------------------------------
07-Jan-2017 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Fresenius Medical Care AG & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
Phone: +49 (0) 6172- 609 2525
Fax: +49 (0) 6172- 609 2301
E-mail: [email protected]
Internet: www.freseniusmedicalcare.com
ISIN: DE0005785802, ,
WKN: 578580, 578583
Indices: DAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange; NYSE
End of Announcement DGAP News Service
---------------------------------------------------------------------------
534707 07-Jan-2017 CET/CEST
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Fresenius Medical Care AG & Co. KGaA ISIN: DE0005785802 können Sie bei EQS abrufen
Medtech , 578580 , FME , XETR:FME